Testing version — LOERadar is in active testing. Features and data may change.

QINLOCK (RIPRETINIB) | LOERadar

Viewing data from:

QINLOCK

NDA

RIPRETINIB | N213973 | DECIPHERA PHARMACEUTICALS LLC

1 strength41 unique patents1 unique exclusivity

Patent Timeline

41 unique patents, 1 exclusivity by expiration date

Active (41)TodayExclusivity

2026

2027

2028

2029

2030

2031

2032

2033

2034

2035

2036

2037

2038

2039

2040

2041

2042

2043

Today

Jun. 7, 2032

Jul. 27, 2030

May. 15, 2034

Aug. 12, 2040

Dec. 30, 2040

Aug. 12, 2040

Aug. 12, 2040

Dec. 30, 2040

Aug. 12, 2040

Aug. 12, 2040

Aug. 12, 2040

Aug. 12, 2040

Dec. 30, 2040

Aug. 12, 2040

Dec. 30, 2040

Oct. 6, 2042

Dec. 30, 2040

Dec. 30, 2040

Aug. 12, 2040

Dec. 30, 2040

Dec. 30, 2040

Dec. 30, 2040

Dec. 30, 2040

Dec. 30, 2040

Dec. 30, 2040

Dec. 30, 2040

Feb. 8, 2041

Dec. 30, 2040

Aug. 12, 2040

Aug. 12, 2040

Aug. 12, 2040

Dec. 30, 2040

Aug. 12, 2040

Aug. 12, 2040

Dec. 30, 2040

Dec. 30, 2040

Dec. 30, 2040

Dec. 30, 2040

Aug. 12, 2040

Aug. 12, 2040

Dec. 30, 2040

ODE-298

May. 15, 2027

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

No ANDA patent litigation cases (NOS 835) matched from PACER

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

No clinical trials found on ClinicalTrials.gov for this drug

Medicare Part D Spending

CMS annual spending data for Qinlock (2023)

Total Spending

$52.1M

Total Claims

1,279

Beneficiaries

255

Avg Cost/Unit

$435.16

Spending Trend

$16.4M(2020)→$37.0M(2021)→$44.8M(2022)→$52.1M(2023)

YoY Change:+7.2%

5yr CAGR:+6.1%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain1 active DMF

1 active API supplier hold Drug Master Files for this ingredient. Limited supplier base — potential supply chain risk.

DR REDDYS LABORATORIES LTDRIPRETINIB

DMF 395082024

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

6 letters from Drugs@FDA

Date	Submission	Document
May 8, 2025	SUPPL -10	View Letter (PDF)
Oct 27, 2023	SUPPL -7	View Letter (PDF)
Jan 3, 2023	SUPPL -4	View Letter (PDF)
Sep 16, 2022	SUPPL -3	View Letter (PDF)
Jun 22, 2021	SUPPL -1	View Letter (PDF)
May 19, 2020	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (1)

#001 — 50MG

RLD

41 patents1 exclusivity▴

TABLET;ORAL | Approved: May 15, 2020

Patents (41)

Patent #	Expiration	PED	Drug Substance	Drug Product	Use Code	Delist
RE48731	Jun 7, 2032	—	—	—		—
8188113	Jul 27, 2030	—	Yes	Yes	—	—
8461179	May 15, 2034	—	Yes	Yes	—	—
10966966	Aug 12, 2040	—	—	—		—
11185535	Dec 30, 2040	—	—	Yes	—	—
11266635	Aug 12, 2040	—	—	—		—
11344536	Aug 12, 2040	—	—	—		—
11395818	Dec 30, 2040	—	—	Yes	—	—
11426390	Aug 12, 2040	—	—	—		—
11433056	Aug 12, 2040	—	—	—		—
11529336	Aug 12, 2040	—	—	—		—
11534432	Aug 12, 2040	—	—	—		—
11576903	Dec 30, 2040	—	—	Yes	—	—
11576904	Aug 12, 2040	—	—	—		—
11612591	Dec 30, 2040	—	—	Yes	—	—
11779572	Oct 6, 2042	—	—	—		—
11793795	Dec 30, 2040	—	—	Yes	—	—
11801237	Dec 30, 2040	—	—	Yes		—
11813251	Aug 12, 2040	—	—	—		—
11844788	Dec 30, 2040	—	—	Yes	—	—
11850240	Dec 30, 2040	—	—	Yes	—	—
11850241	Dec 30, 2040	—	—	Yes	—	—
11896585	Dec 30, 2040	—	—	Yes	—	—
11903933	Dec 30, 2040	—	—	Yes	—	—
11911370	Dec 30, 2040	—	—	Yes	—	—
11918564	Dec 30, 2040	—	—	Yes	—	—
11969414	Feb 8, 2041	—	—	—		—
11969415	Dec 30, 2040	—	—	—		—
12023325	Aug 12, 2040	—	—	—		—
12023326	Aug 12, 2040	—	—	—		—
12023327	Aug 12, 2040	—	—	—		—
12023328	Dec 30, 2040	—	—	—		—
12059410	Aug 12, 2040	—	—	—		—
12059411	Aug 12, 2040	—	—	—		—
12064422	Dec 30, 2040	—	—	—		—
12213967	Dec 30, 2040	—	—	Yes	—	—
12213968	Dec 30, 2040	—	—	Yes	—	—
12226406	Dec 30, 2040	—	—	Yes	—	—
12295944	Aug 12, 2040	—	—	—		—
12318373	Aug 12, 2040	—	—	—		—
12318374	Dec 30, 2040	—	—	Yes	—	—

Exclusivities (1)

Code	Date	Status
ODE-298	May 15, 2027	< 1 year